R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433

British Journal of Haematology

Volumn 166, Issue 3, 2014, Pages 382-389

  Friedberg, Jonathan W ^a   Unger, Joseph M ^b   Burack, W Richard ^a   Gopal, Ajay K ^c   Raju, Robert N ^d   Nademanee, Auayporn P ^e   Kaminski, Mark S ^f   Li, Hongli ^b   Press, Oliver W ^c,g   Miller, Thomas P ^h   Fisher, Richard I ^a,i  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Dayton Clinical Oncology Program CCOP Hematology and Oncology of Dayton Inc   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapeutic approaches; Diffuse large B cell lymphoma; Lymphoma; Pharmacotherapeutics; Radioimmunotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; DEHYDRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERMINAL CENTER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RECTUM HEMORRHAGE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

CHEMOTHERAPEUTIC APPROACHES; DIFFUSE LARGE B CELL LYMPHOMA; LYMPHOMA; PHARMACOTHERAPEUTICS; RADIOIMMUNOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; VINCRISTINE;

EID: 84904039513     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12906     Document Type: Article

References (37)

1. Anderson, J.R., Cain, K.C. & Gelber, R.D. (1983) Analysis of survival by tumor response. Journal of Clinical Oncology, 1, 710-719.
2. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
3. Chiappella, A., Tucci, A., Castellino, A., Pavone, V., Baldi, I., Carella, A.M., Orsucci, L., Zanni, M., Salvi, F., Liberati, A.M., Gaidano, G., Bottelli, C., Rossini, B., Perticone, S., De Masi, P., Ladetto, M., Ciccone, G., Palumbo, A., Rossi, G. & Vitolo, U. (2013) Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 98, 1732-1738.
4. Coiffier, B., Lepage, E., Briã̈re, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
5. Cox, D. (1972) Regression models and life tables. Journal of the Royal Statistical Society, 34, 187-220.
6. Crump, M., Coiffier, B., Jacobsen, E.D., Sun, L., Ricker, J.L., Xie, H., Frankel, S.R., Randolph, S.S. & Cheson, B.D. (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Annals of Oncology, 19, 964-969.
7. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferm, C.A., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
8. Friedberg, J.W. (2011) New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clinical Cancer Research, 17, 6112-6117.
9. Friedberg, J.W. (2012) Double-hit diffuse large B-cell lymphoma. Journal of Clinical Oncology, 30, 3439-3443.
10. Friedberg, J.W., Kim, H., McCauley, M., Hessel, E.M., Sims, P., Fisher, D.C., Nadler, L.M., Coffman, R.L. & Freedman, A.S. (2005) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood, 105, 489-495.
11. Friedberg, J.W., Kelly, J.L., Neuberg, D., Peterson, D.R., Kutok, J.L., Salloum, R., Brenn, T., Fisher, D.C., Ronan, E., Dalton, V., Rich, L., Marquis, D., Sims, P., Rothberg, P.G., Liesveld, J., Fisher, R.I., Coffman, R., Mosmann, T. & Freedman, A.S. (2009) Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology, 146, 282-291.
12. Gopal, A.K., Press, O.W., Wilbur, S.M., Maloney, D.G. & Pagel, J.M. (2008) Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood, 112, 830-835.
13. Green, D.J., Pagel, J.M., Pantelias, A., Hedin, N., Lin, Y., Wilbur, D.S., Gopal, A., Hamlin, D.K. & Press, O.W. (2007) Pretargeted radioimmunotherapy for B-cell lymphomas. Clinical Cancer Research, 13(18 Pt 2), 5598s-5603s.
14. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Moller, M.B. (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
15. Hamlin, P.A. Jr, Rodriguez, M.A., Noy, A., Portlock, C.S., Straus, D., McLaughlin, P., Pro, B., Fayad, L., Hagemeister, F., Wegner, B., Dumitrescu, O., Tasker, N.P., Moskowitz, C.H. & Zelenetz, A.D. (2010) Final results of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Blood, 116, 1793.
16. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
17. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
18. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the Americal Statistical Association, 53, 457-481.
19. Lawless, J.F. (1982). Statistical Models and Methods for Lifetime Data. John Wiley and Sons, New York, NY.
20. Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M., Lymphoma/Leukemia Molecular Profiling (2008) Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine, 359, 2313-2323.
21. Miller, T.P., Unger, J.M., Spier, C., Stea, B., Press, O.W., Friedberg, J.W., LeBlanc, M. & Fisher, R.I. (2008) Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood, 112, 3598.
22. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P.L., Rule, S., Liberati, A.M., Milpied, N., Hess, G., Stein, H., Kalmus, J. & Marcus, R. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, 54-58.
23. Morschhauser, F., Kraeber-Bodere, F., Wegener, W.A., Harousseau, J.L., Petillon, M.O., Huglo, D., Trumper, L.H., Meller, J., Pfreundschuh, M., Kirsch, C.M., Naumann, R., Kropp, J., Horne, H., Teoh, N., Le Gouill, S., Bodet-Milin, C., Chatal, J.F. & Goldenberg, D.M. (2010) High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 3709-3716.
24. Pfreundschuh, M. (2012) Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. Journal of Clinical Oncology, 30, 3433-3435.
25. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
26. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M., German High-Grade Non-Hodgkin Lymphoma Study (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology, 9, 105-116.
27. Press, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., LeBlanc, M., Gaynor, E.R., Rivkin, S.E. & Fisher, R.I. (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood, 102, 1606-1612.
28. Press, O.W., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., Leblanc, M. & Fisher, R.I., Southwest Oncology (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. Journal of Clinical Oncology, 24, 4143-4149.
29. Press, O.W., Unger, J.M., Rimsza, L.M., Friedberg, J.W., LeBlanc, M., Czuczman, M.S., Kaminski, M., Braziel, R.M., Spier, C., Gopal, A.K., Maloney, D.G., Cheson, B.D., Dakhil, S.R., Miller, T.P. & Fisher, R.I. (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology, 31, 314-320.
30. Schaefer-Cutillo, J. & Friedberg, J.W. (2008) Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. Seminars in Hematology, 45, 110-117.
31. Stiff, P.J., Unger, J.M., Cook, J.R., Constine, L.S., Couban, S., Stewart, D.A., Shea, T.C., Porcu, P., Winter, J.N., Kahl, B.S., Miller, T.P., Tubbs, R.R., Marcellus, D., Friedberg, J.W., Barton, K.P., Mills, G.M., LeBlanc, M., Rimsza, L.M., Forman, S.J. & Fisher, R.I. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 369, 1681-1690.
32. Vose, J.M., Carter, S., Burns, L.J., Ayala, E., Press, O.W., Moskowitz, C.H., Stadtmauer, E.A., Mineshi, S., Ambinder, R., Fenske, T., Horowitz, M., Fisher, R. & Tomblyn, M. (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. Journal of Clinical Oncology, 31, 1662-1668.
33. Witzig, T.E., Wiseman, G.A., Maurer, M.J., Habermann, T.M., Micallef, I.N., Nowakowski, G.S., Ansell, S.M., Colgan, J.P., Inwards, D.J., Porrata, L.F., Link, B.K., Zent, C.S., Johnston, P.B., Shanafelt, T.D., Allmer, C., Asmann, Y.W., Gupta, M., Ballas, Z.K., Smith, B.J. & Weiner, G.J. (2013) A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. American Journal of Hematology, 88, 589-593.
34. Younes, A., Flinn, I., Berdeja, J.G., Friedberg, J.W., Alberti, S., Thieblemont, C., Morschhauser, F., Hellemans, P., Hall, B., Smit, J., Skee, D., de Vries, R., Todorovic, M., Khan, I., Fourneau, N. & Oki, Y. (2013) Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology, 31(Suppl. 15), 8502.
35. Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 2373-2380.
36. Zinzani, P.L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S. & Baccarani, M. (2008) A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Annals of Oncology, 19, 769-773.
37. Zinzani, P.L., Rossi, G., Franceschetti, S., Botto, B., Di Rocco, A., Cabras, M.G., Petti, M.C., Stefoni, V., Broccoli, A., Fanti, S., Pellegrini, C., Montini, G.C., Gandolfi, L., Derenzini, E., Argnani, L., Fina, M., Tucci, A., Bottelli, C., Pileri, S. & Baccarani, M. (2010) Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clinical Cancer Research, 16, 3998-4004.